Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTA vs METROCREAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Rosacea (inflammatory papules and pustules),Topical treatment of bacterial vaginosis (off-label)
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Topical, apply a thin film to affected area once or twice daily.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Hepatic metabolism via oxidation and glucuronidation. Metronidazole is metabolized by CYP450 enzymes, primarily CYP2A6 and CYP3A4, forming metabolites such as hydroxy metronidazole and acetic acid metabolite.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Metronidazole: <20% bound to plasma proteins.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Vd: ~0.6-0.7 L/kg, indicating distribution into total body water.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Topical: Systemic bioavailability approximately 0.1-1% of applied dose for metronidazole 1% cream.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No adjustment required for topical application.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
No adjustment required for topical application.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Safety and efficacy not established in pediatric patients under 18 years.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
No specific dose adjustment recommended; use caution due to potential skin atrophy.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
None
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Avoid contact with eyes. Use with caution in patients with blood dyscrasias or history of hypersensitivity to metronidazole. Prolonged use may result in overgrowth of non-susceptible organisms. Discontinue if irritation occurs.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Hypersensitivity to metronidazole or any component of the formulation.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
No significant food interactions due to negligible systemic absorption. However, alcohol consumption should be avoided during treatment and for at least 48 hours after discontinuing metronidazole, as trace systemic absorption may cause disulfiram-like reactions (nausea, vomiting, flushing, headache).
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Topical metronidazole (Metro Cream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, data do not suggest an increased risk of major malformations; however, use in first trimester is generally avoided due to theoretical risk. For topical application, systemic absorption is minimal (approximately 2%), and the drug is considered safe throughout pregnancy, with no known fetal risks.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Minimal systemic absorption of metronidazole after topical application (approximately 2%) results in negligible transfer into breast milk. M/P ratio is not established for topical route. Use during breastfeeding is considered compatible; however, avoid application to breast area to prevent infant exposure.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
No dosage adjustment is necessary during pregnancy. Systemic absorption from topical application is minimal and pharmacokinetic changes in pregnancy do not warrant dose modification.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Metronidazole topical cream is contraindicated in patients with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. Avoid contact with eyes, mucous membranes, or open wounds. Use during pregnancy only if clearly needed (FDA category B). Warn patients that topical metronidazole may cause transient skin irritation or dryness; if severe, discontinue use. Combine with sunscreen and photoprotective measures due to potential photosensitivity. For rosacea, clinical improvement may take 3–4 weeks; adherence is critical. Do not use with concomitant oral metronidazole or disulfiram-like reactions due to minimal systemic absorption.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
Apply a thin layer to affected areas once or twice daily as directed.,Wash hands before and after application; avoid contact with eyes, mouth, and nostrils.,Do not use cosmetics or other skin products on treated areas unless approved by your doctor.,May cause mild stinging, burning, or dryness; if severe, stop use and inform your physician.,Minimize sun exposure and use sunscreen daily as metronidazole may increase sun sensitivity.,Notify your doctor if you develop signs of allergic reaction: rash, itching, swelling, or trouble breathing.,Do not use more than prescribed; extended use may lead to bacterial resistance.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before using.,Inform your doctor if you are taking oral metronidazole or have a history of blood disorders or neuropathy.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTA vs METROCREAM, answered by our medical review team.
ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. METROCREAM is a Antibiotic (Nitroimidazole) that works by Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTA and METROCREAM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. The standard adult dose of METROCREAM is: Topical, apply a thin film to affected area once or twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTA and METROCREAM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. METROCREAM is classified as Category C. Topical metronidazole (MetroCream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, da. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.